Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis.

OBJECTIVE The role of estrogens in rheumatoid arthritis (RA) is debated since both proinflammatory and antiinflammatory effects have been reported. Important evidence of the dual role of estrogens is conversion to various proinflammatory or antiinflammatory metabolites. This study was undertaken to examine the downstream conversion of estrogens in synovial cells from patients with RA or osteoarthritis (OA). METHODS We studied serum levels of estrone, estrone sulfate, and estrone sulfate membrane transporters, intracellular interconversion of estrone and 17beta-estradiol, and conversion of estrone/17beta-estradiol to various estrogen metabolites in RA and OA synovial cells. The effect of estrogen metabolites on tumor necrosis factor (TNF) secretion was also studied in RA and OA synovial cells. RESULTS Serum levels of estrone sulfate were similar in healthy controls and RA patients. Estrone sulfate transporters were present in synovial tissue. Interconversion of estrone and 17beta-estradiol and the expression of converting enzymes of the cytochrome P450 family were similar in RA and OA cells. Using estrone and 17beta-estradiol as substrates, RA and OA synovial cells produced 16alpha-, 4-, and 2-hydroxylated estrogens and their 4- and 2-methylation products. The levels of 16alpha-hydroxylated estrone/17beta-estradiol (16alphaOH-estrone/16alphaOH-17beta-estradiol) were higher than the levels of all other estrogen metabolites. RA synovial cells produced more 16alphaOH-estrone than did OA synovial cells. Importantly, the 16alphaOH estrogens did not inhibit TNF secretion, whereas all other estrogen metabolites had marked inhibitory effects. CONCLUSION Our findings indicate that precursor estrogens are converted to proinflammatory metabolites, particularly in RA synovial cells. RA synovial cells mainly produce the proproliferative 16alphaOH-estrone, which, in addition to 16alphaOH-17beta-estradiol, is one of the only 2 estrogens studied that does not inhibit TNF secretion. A preponderance of 16alpha-hydroxylated estrogens is an unfavorable sign in synovial inflammation.

[1]  R. Straub,et al.  Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. , 2008, Clinical and experimental rheumatology.

[2]  R. Straub,et al.  The complex role of estrogens in inflammation. , 2007, Endocrine reviews.

[3]  M. Hochberg,et al.  Estradiol and its metabolites and their association with knee osteoarthritis. , 2006, Arthritis and rheumatism.

[4]  J. Yager,et al.  Estrogen carcinogenesis in breast cancer. , 2006, The New England journal of medicine.

[5]  J. Schölmerich,et al.  Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes – androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5α-reduced androgens , 2005, Arthritis research & therapy.

[6]  J. Schölmerich,et al.  Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: a prerequisite for local androgen deficiency. , 2005, Arthritis and rheumatism.

[7]  E. Jackson,et al.  Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. , 2005, Cardiovascular research.

[8]  A. Boots,et al.  CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines. , 2005, Arthritis and rheumatism.

[9]  M. Cutolo,et al.  Estrogens and arthritis. , 2005, Rheumatic diseases clinics of North America.

[10]  L. Zacharia,et al.  Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. , 2005, The Journal of clinical endocrinology and metabolism.

[11]  J. Schölmerich,et al.  Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[12]  J. Schölmerich,et al.  Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. , 2004, The Journal of rheumatology.

[13]  R. Straub,et al.  Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. , 2003, The Journal of rheumatology.

[14]  X. Shu,et al.  Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection , 2003, Steroids.

[15]  E. Jackson,et al.  2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. , 2002, Journal of the American Society of Nephrology : JASN.

[16]  E. Jackson,et al.  Invited Review: Cardiovascular protective effects of 17β-estradiol metabolites , 2001 .

[17]  P. Neuhaus,et al.  The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors , 2001, Journal of Cancer Research and Clinical Oncology.

[18]  F. Berrino,et al.  Estrogen Metabolism and Risk of Breast Cancer: a Prospective Study of the 2:16␣-hydroxyestrone Ratio in Premenopausal and Postmenopausal Women , 2022 .

[19]  R. Straub,et al.  The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  M. Cutolo,et al.  Endocrine End‐Points in Rheumatoid Arthritis a , 1999, Annals of the New York Academy of Sciences.

[21]  B. Bresnihan,et al.  Microscopic measurement of synovial membrane inflammation in rheumatoid arthritis: proposals for the evaluation of tissue samples by quantitative analysis. , 1998, British journal of rheumatology.

[22]  G. Löffler,et al.  Induction of aromatase activity in human adipose tissue stromal cells by extracellular nucleotides--evidence for P2-purinoceptors in adipose tissue. , 1998, European journal of biochemistry.

[23]  E. Josefsson,et al.  Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. , 1997, Arthritis and rheumatism.

[24]  M. Osborne,et al.  2-hydroxyestrone: the 'good' estrogen. , 1996, The Journal of endocrinology.

[25]  M. Osborne,et al.  Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. , 1992, Journal of the National Cancer Institute.

[26]  F. Greenspan.  Basic and Clinical Endocrinology , 1990 .

[27]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[28]  J. Lefebvre,et al.  Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation , 1989, Molecular and Cellular Endocrinology.

[29]  J. Fishman,et al.  Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[31]  H. Bradlow,et al.  Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. , 1984, The Journal of biological chemistry.

[32]  H. Kunkel,et al.  Alterations of estrogen metabolism in systemic lupus erythematosus. , 1979, Arthritis and rheumatism.

[33]  H. Kunkel,et al.  Systemic lupus erythematosus associated with klinefelter's syndrome. , 1977, Arthritis and rheumatism.